2021 was a record year for investments in UK biotech companies, consolidating the country's position as one of Europe's top life science hubs and apparently shrugging off the effects of the
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna Campbell-Gray.
The process of discovering HCPs who are leading key opinion leaders (KOLs) in emerging and growing markets is not as straightforward as it is in other countries.